Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 400 for:    PYY

Appetite Regulation and Mycoprotein (mycoprotein)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02053025
Recruitment Status : Completed
First Posted : February 3, 2014
Last Update Posted : August 27, 2015
Sponsor:
Information provided by (Responsible Party):
Imperial College London

Brief Summary:
The purpose of this study is to investigate the effect of eating various levels of mycoprotein (Quorn) on feelings of appetite, energy intake and levels of gut hormones in overweight volunteers.

Condition or disease Intervention/treatment Phase
Appetite Energy Intake Dietary Supplement: mycoprotein Dietary Supplement: control protein Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Appetite Regulation and Mycoprotein
Study Start Date : March 2010
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Arm Intervention/treatment
Active Comparator: mycoprotein
3 levels of mycoprotein will be consumed
Dietary Supplement: mycoprotein
Active Comparator: control protein
3 levels of a control protein will be consumed
Dietary Supplement: control protein



Primary Outcome Measures :
  1. Energy intake at ad-libitum meal [ Time Frame: upon completion of all participants, expected timeframe: 2 years ]
    Energy intake will be assessed during an ad-libitum meal at 180 minutes at the end of each study visit. Participants will be offered a meal in excess and asked to eat until they feel comfortably full. The meal will be weighed before and after consumption and energy intake will be calculated from the manufacturer's reported nutritional composition.


Secondary Outcome Measures :
  1. Glucagon-like peptide-1 (GLP-1) [ Time Frame: upon completion of all participants, expected at 2 years ]
    Plasma glucagon-like peptide-1 (GLP-1) concentrations will be measured by radioimmunoassay (RIA) at the end of the study

  2. peptide tyrosine-tyrosine (PYY) levels [ Time Frame: upon completion of all participants, expected at 2 years ]
    Plasma peptide tyrosine-tyrosine (PYY) concentrations will be measured by radioimmunoassay (RIA) at the end of the study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and females between the ages of 18 and 65
  • body mass index (BMI) 25-32kg/m2
  • Weight stable over the past 6 months
  • No known major illness or eating disorder nor on any medication that may impact on appetite or hormone levels.
  • No paracetamol or other analgesic in the previous 48 hours
  • A score of <2.5 in the Dutch Eating Behaviour Questionnaire (DEBQ)
  • A score of <2 in the SCOFF questionnaire

Exclusion Criteria:

  • Persons outside the age and BMI ranges stated above
  • Pregnant and lactating women
  • Weight variation of greater than 5% in the last 6 months
  • Any diagnosed major illness
  • Any paracetamol or analgesic intake in the last 48 hours
  • Diagnosed eating disorder
  • Allergy to mycoprotein or mushrooms
  • Regular consumption of Quorn products
  • Dislike of any of the test foods or drinks
  • A score of >2.5 in the Dutch Eating Behaviour questionnaire
  • A score of 2 or more in the SCOFF questionaire

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02053025


Locations
Layout table for location information
United Kingdom
Imperial College NIHR CRF
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Imperial College London
Investigators
Layout table for investigator information
Principal Investigator: Gary Frost Imperial College London

Layout table for additonal information
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT02053025     History of Changes
Other Study ID Numbers: CRO1332
First Posted: February 3, 2014    Key Record Dates
Last Update Posted: August 27, 2015
Last Verified: January 2014

Keywords provided by Imperial College London:
appetite
overweight
energy intake
obesity
gut hormones